An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Nucleosides containing arabinose as their sugar moiety.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Studies beyond the bachelor's degree at an institution having graduate programs for the purpose of preparing for entrance into a specific field, and obtaining a higher degree.
The teaching staff and members of the administrative staff having academic rank in an educational institution.
Individuals enrolled in a school or formal educational program.
Educational programs for pharmacists who have a bachelor's degree or a Doctor of Pharmacy degree entering a specific field of pharmacy. They may lead to an advanced degree.
The teaching staff and members of the administrative staff having academic rank in a medical school.
Auditory and visual instructional materials.
The educational process of instructing.
Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with ... The four phases of the cell cycle. G1 - the initial growth phase. S - the phase in which DNA is synthesised. G2 - the second ... Patients frequently fail to understand its limitations. In one study of patients who had been newly diagnosed with incurable, ... Cardiotoxicity (heart damage) is especially prominent with the use of anthracycline drugs (doxorubicin, epirubicin, idarubicin ...
Acute myeloid leukemia, excluding acute promyelocytic leukemia DAT daunorubicin, cytarabine (ara-C), tioguanine Acute myeloid ... fludarabine, cytarabine, idarubicin, G-CSF relapsed or refractory acute myelogenous leukemia FLAG-Mito or FLAG-MITO or Mito- ... non-Hodgkin lymphoma in patients with history of cardiovascular disease COPP cyclophosphamide, Oncovin (vincristine), ... "A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) ...
Specifically it is used to treat acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ... February 2011). "Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME ... It is used to treat acute lymphocytic leukemia, Crohn's disease, and ulcerative colitis.[7] ... S phase). Folic acid. *Dihydrofolate reductase inhibitor (Aminopterin. *Methotrexate#. *Pemetrexed. *Pralatrexate). * ...
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. „J Clin ... Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 ... acute myeloid leukemia lub acute myelogenous leukemia, AML lub acute non-lymphoblastic leukemia, ANLL) - grupa chorób ... A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by ...
... idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid ... Moreover, vinca alkaloids in the context of AML cause AML cells to undergo a cell cycle arrest in the phase that renders those ... lowering the chance of the patient to get remission. This is because vinca alkaloids are rapidly deactivated in myeloid cells ... in acute myelogenous leukemia, excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or ...
Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk ... "Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour ... "Final Results of Phase 2, Open-Label Study of E7070, ... Infusion Every Three Weeks in Patients With Advanced Cancer". ...
"Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia". ... of patients. A Phase I study of 47 patients reported in 2010 that treatment of refractory neuroblastoma was well tolerated at ... as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy". Blood. ... A multi-center Phase II study of 29 patients above the age of 60 was initiated for treatment with lestaurtinib alone; the ...
The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with ... This means that they only work during a specific part of the cell cycle, in this case S-phase (the DNA synthesis phase). For ... As more than half of cancer patients are elderly, this adverse effect is only relevant for a minority of patients. A study in ... Derivatives of these compounds include epirubicin and idarubicin. Other clinically used drugs in the anthracycline group are ...
October 2007). "Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid ... which damages DNA when the cell cycle holds in the S phase (synthesis of DNA). Rapidly dividing cells, which require DNA ... Cytarabine is mainly used in the treatment of acute myeloid leukaemia, acute lymphocytic leukaemia (ALL) and in lymphomas, ... is a chemotherapy medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous ...
... acute lymphoblastic leukemia - acute lymphocytic leukemia - acute myelogenous leukemia - acute myeloid leukemia - acute ... phase I trial - phase I/II trial - phase II trial - phase II/III trial - phase III trial - phase IV trial - phenethyl ... patient-controlled analgesia - Patient derived tumor xenografts - PCA - PDQ - peau d'orange - PEG-interferon alfa-2a - PEG- ... idarubicin - IDEC-Y2B8 monoclonal antibody - idiopathic - idiopathic myelofibrosis - idoxifene - idoxuridine - ifosfamide - ...
October 2009). "A phase 2 study of vorinostat in acute myeloid leukemia". Haematologica. 94 (10): 1375-82. doi:10.3324/haematol ... "Zolinza, Idarubicin, Cytarabine Combination Yields High Response Rates In MDS Patients (ASH 2011)". Clinical trial number ... It also failed to demonstrate efficacy in treating acute myeloid leukemia in a phase II study. Vorinostat has been shown to ... It has given encouraging results in a phase II trial for myelodysplastic syndromes in combination with idarubicin and ...
This mutation impacts patients with acute myeloid leukemia (AML) by initially responding to chemotherapy but relapsing ... Arno Therapeutics (2014-12-08). "A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) in Adult Patients ... Idarubicin (a daunorubicin derivative) Idarubicin is able to pass through cell membranes easier than daunorubicin and ... In this study, 45 patients had hypermethylated WRN gene promoters and 43 patients had unmethylated WRN promoters. Irinotecan ...
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid ... Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 ... Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience * ... High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361: 1235-1248. ...
This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid ... Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML ... Phase Acute Biphenotypic Leukemia Acute Myeloid Leukemia Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Blasts 10 ... Core binding factor acute myeloid leukemia Cytogenetically normal acute myeloid leukemia Familial acute myeloid leukemia with ...
Venetoclax and Cytarabine with or without Idarubicin Hydrochloride in Treating Pediatric Patients with Refractory or Relapsed ... Giving venetoclax, cytarabine, and idarubicin hydrochloride may work better in treating pediatric patients with acute myeloid ... This phase I trial studies the side effects and best dose of venetoclax and cytarabine when given with or without idarubicin ... Cytarabine with or without Idarubicin Hydrochloride in Treating Pediatric Patients with Refractory or Relapsed Acute Myeloid ...
Response rate (Phase II). Secondary Outcome Measures : *Toxicity as assessed by CTCAE v3.0 (Phase II). *Response rate (Phase I) ... adult acute myeloid leukemia with t(16;16)(p13;q22). adult acute myeloid leukemia with t(8;21)(q22;q22). adult acute myeloid ... Core binding factor acute myeloid leukemia Cytogenetically normal acute myeloid leukemia Familial acute myeloid leukemia with ... Idarubicin Clofarabine Genetic and Rare Diseases Information Center resources: Myeloid Leukemia Acute Myeloid Leukemia Acute ...
Phase Myelodysplastic Syndrome Acute Myeloid Leukemia Drug: Idarubicin Drug: Cytarabine Drug: Lenalidomide (Revlimid®) Phase 1 ... Core binding factor acute myeloid leukemia Cytogenetically normal acute myeloid leukemia Familial acute myeloid leukemia with ... Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML). The ... Idarubicin and Cytarabine combination therapy is a standard treatment for patients with acute myeloid leukemia (AML). ...
Recurrent Adult Acute Myeloid Leukemia Drug: Cytarabine Drug: Ibrutinib Drug: Idarubicin Phase 1 ... Idarubicin Ibrutinib Genetic and Rare Diseases Information Center resources: Myeloid Leukemia Acute Myeloid Leukemia Acute Non ... Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia. The safety and ... A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia. ...
... cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia, 28(7), 1543-1545. ... Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute ... Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute ... Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute ...
This phase I/II trial is studying the side effects and best dose of bendamustine hydrochloride when given together with ... 50 With Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome. Trial Phase:. Phase 1/Phase 2. ... Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid ... Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid ...
... or Refractory or Blastic Phase Chronic Myelogenous Leukemia PXD101 in Treating Patients With Acute Myeloid Leukemia Decitabine ... and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia Sirolimus and Azacitidine in Treating Patients With ... MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia. May ... MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia. ...
This single-arm, phase 2 part of the phase 1-2 study of nivolumab in combination with idarubicin and cytarabine was done at the ... Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic ... "Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic ... Outcomes for younger patients with acute myeloid leukaemia have moderately improved over the past two decades owing to better ...
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid ... Refractory Anemia With Excess Blasts in Transformation Completed Phase 1 / 2 Trials for Idarubicin (DB01177). Back to ... Also known as: Refractory anemia with excess blasts in transformation / Acute myeloblastic leukemia, minimal differentiation / ...
ADMIRAL was a randomized, phase III clinical trial designed to determine whether gilteritinib improved survival for patients ... and idarubicin. ... Gilteritinib Improved Survival for Patients With Acute Myeloid ... improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation compared with ... Of the 371 patients enrolled in the clinical trial, 247 were randomly assigned to gilteritinib and 124 to standard chemotherapy ...
Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Not Recruiting This phase I ... A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML) 52nd Annual ... Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia ... Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to ...
Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Not Recruiting This phase I ... A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia BLOOD Nand, S., ... A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood Nand, S ... A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML) 52nd Annual ...
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid ... Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid ... Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid ... Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid ...
... phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid ... A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid ... Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. ... Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute ...
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid ... Phase 1 Study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011;96(1):62-68. ... Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 ... Activating mutations of the Fms-like tyrosine kinase-3 gene (FLT3) occur in ∼ 30% of patients with acute myeloid leukemia (AML ...
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic ... syndrome: a single-arm, phase 2 study.. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, ... Design of the patient navigator to Reduce Readmissions (PArTNER) study: A pragmatic clinical effectiveness trial. ... Enhancing Medication Adherence through Improved Patient-provider Communication: The 6As of Intervention. ...
A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who ... in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid ... Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic ... Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical ...
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid ... Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated ... Chronic Myelomonocytic Leukemia Completed Phase 1 / 2 Trials for Tipifarnib (DB04960). Back to Chronic Myelomonocytic Leukemia ...
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or ... A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or ... Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells ... Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. Blood 119: 5215-5220. ...
... non-controlled open-label phase II trial to evaluate the safety and e... ... A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid ... Acute myeloid leukaemia presenting with bilateral breast masses.. A 46-year-old woman with a known history of acute myeloid ... Leukemia, Myeloid, Acute. Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop ...
A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and ... A phase 2 randomized study of low dose Ara-C with or without glasdegib (PF-04449913) in untreated patients with acute myeloid ... Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin ... Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a ...
Title: A Phase II Study of Bevacizumab (rhuMAB VEGF, NSC#704865), Idarubicin, and Cytarabine in Patients with Chronic Myeloid ... Acute Myelogenous Leukemia (AML). Title: Phase II Study of Bevacizumab, Cytarabine, andMitoxantrone in Patients With Poor-Risk ... Title: Phase II Study of Concurrent Bevacizumab andVinorelbine in Patients With Stage IV Breast Cancer. Protocol Number: NCI- ... Title: Phase I/II Study of Bevacizumab in Patients WithMyelodysplastic Syndrome. Protocol Number: NCI-2771. Participating ...
... and Idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J. Clin. Oncol. 21:1722- ... 1. New designs for clinical trials - patients and physician are poorly served by the current phase 1-phase 2-phase 3 paradigm. ... Acute myeloid leukemia and myelodysplastic syndromes in older patients. J. Clin. Oncol. 25:1908-1915, 2007.. Estey E, de Lima M ... acute myeloid leukemia patients. Blood 113:28-36, 2009. Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, ...
... intensity conditioning regimen prior to allogeneic stem-cell transplantation had similar 2-year survival outcomes as patients ... Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic ... Prospective Phase 2 Study of Umbilical Cord Blood Transplantation in Adult Acute Leukemia and Myelodysplastic Syndrome ... but the prognostic value of SF in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients and the impact of ...
This phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high- ... This phase II trial studies how well cytarabine and idarubicin or venetoclax, azacitidine and decitabine work in treating ... This phase II trial investigates how well fludarabine and CPX-351 work in treating patients with newly-diagnosed acute myeloid ... CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger than 60 Years Old This phase II trial studies ...
Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic ... This phase II trial studies how well cytarabine and idarubicin or decitabine work in treating patients with acute myeloid ... A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome ... Cytarabine and Idarubicin or Decitabine in Treating Older Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic ...
Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk ... "Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour ... "Final Results of Phase 2, Open-Label Study of E7070, ... Infusion Every Three Weeks in Patients With Advanced Cancer". ...
Acute myeloid leukemia , FLT3-mutated Acute Myeloid Leukemia , A Study of ASP2215 in Combination With Induction and ... Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. ... in newly diagnosed Acute Myeloid Leukemia (AML) subjects. Phase 1 part will also evaluate safety and tolerability and ... of ASP2215 concomitant with cytarabine/idarubicin as induction chemotherapy based on the status of the onset of dose-limiting ...
  • Outcomes for younger patients with acute myeloid leukaemia have moderately improved over the past two decades owing to better supportive care and recent introduction of novel targeted agents. (fluidigm.com)
  • We aimed to assess the addition of nivolumab to frontline therapy with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome. (fluidigm.com)
  • 60 years if suitable for intensive chemotherapy), and had newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome, and an Eastern Cooperative Oncology Group performance status of 0-2. (fluidigm.com)
  • Between Aug 7, 2015, and June 2, 2018, 44 patients were enrolled of whom 22 (50%) had adverse genetic risk by European Leukaemia Network classification. (fluidigm.com)
  • The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the body in patients with Acute Myeloid Leukaemia (AML). (bioportfolio.com)
  • The main objective of this study is to assess the biological activity of elacytarabine in combination with idarubicin in patients with acute myeloid leukaemia who has failed the first cour. (bioportfolio.com)
  • Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. (bioportfolio.com)
  • Old age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukaemia are associated with early relapse and poor survival. (bioportfolio.com)
  • The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia. (bioportfolio.com)
  • Acute myeloid leukaemia (AML) is a heterogeneous haematopoietic malignancy. (bioportfolio.com)
  • Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT). (bioportfolio.com)
  • To evaluate the outcomes and prognostic factors following allogeneic haematopoietic cell transplantation (HCT) for adult acute myeloid leukaemia (AML) in second complete remission (CR2), we retrospect. (bioportfolio.com)
  • Acute myeloid leukaemia presenting with bilateral breast masses. (bioportfolio.com)
  • A 46-year-old woman with a known history of acute myeloid leukaemia presented with bilateral breast masses with pain and itchiness. (bioportfolio.com)
  • Systematic review of pre-clinical chronic myeloid leukaemia. (bioportfolio.com)
  • Studies of a provisional entity pre-clinical chronic myeloid leukaemia (CML), which precedes chronic phase (CP) without leucocytosis or blood/marrow feature of CML CP, has been increasing. (bioportfolio.com)
  • The use of arsenic trioxide instead of idarubicin in combination with all-trans retinoic acid is a feasible option in patients with acute promyelocytic leukaemia, regardless of risk level, suggests a phase III trial. (news-medical.net)
  • Introduction Acute myeloid leukaemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells or platelets. (bmj.com)
  • Acute myeloid leukaemia (AML) is a term used to represent a heterogeneous group of diseases resulting from a malignant change in the haematopoietic stem cells. (bmj.com)
  • Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial). (cancerindex.org)
  • This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. (cancerindex.org)
  • The CD34 + CD38 - subset of AML cells is enriched for resistance to current chemotherapeutic agents and considered to contribute to disease progression and relapse in Acute Myeloid Leukaemia (AML) patients following initial treatment. (pubmedcentralcanada.ca)
  • Acute myeloid leukaemia is a disease in which patients tend to respond well to remission induction chemotherapy, but relapse is common because current therapy cannot totally eradicate the leukaemic cells. (pubmedcentralcanada.ca)
  • Selecting initial treatment of acute myeloid leukaemia in older adults. (springermedizin.de)
  • In attempting to restore the chronic phase (CP) of chronic myelogenous leukaemia (CML), the Swedish CML group utilized an intensive chemotherapy protocol for 83 patients (aged 16-79 years) in accelerated (AP, n = 22) or blastic phase (BC, n = 61). (diva-portal.org)
  • Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. (semanticscholar.org)
  • Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. (semanticscholar.org)
  • Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study. (medscape.com)
  • Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. (medscape.com)
  • We therefore aimed to assess the activity of alisertib combined with 7â +â 3 induction chemotherapy in previously untreated patients with high-risk acute myeloid leukaemia. (bvsalud.org)
  • Eligible patients had previously untreated acute myeloid leukaemia, an Eastern Cooperative Oncology Group performance status of 0-2, and were at high risk of disease as defined by the presence of an adverse-risk karyotype, the presence of secondary acute myeloid leukaemia arising from previous myelodysplastic syndrome or myeloproliferative neoplasm, the presence of therapy-related acute myeloid leukaemia, or being 65 years or older. (bvsalud.org)
  • 19 (49%) of 39 patients had secondary acute myeloid leukaemia and three (8%) had therapy-related acute myeloid leukaemia. (bvsalud.org)
  • INTERPRETATION: These results suggest that alisertib combined with induction chemotherapy is active and safe in previously untreated patients with high-risk acute myeloid leukaemia. (bvsalud.org)
  • Acute myeloid leukaemia is a cancer of the blood cells. (cancerinfo.co.in)
  • Unlike chronic myeloid leukaemia which tends to develop slowly, AML grows in a patient quickly over days or weeks. (cancerinfo.co.in)
  • Acute myeloid leukaemia can present in children and adults but is more common in adults, particularly in the older age group with 40% of AML occurring in patients over the age of 75. (cancerinfo.co.in)
  • Acute myeloid leukaemia is divided into different types based on the different classifications that are used. (cancerinfo.co.in)
  • The WHO classification is based on the type of leukaemia cell that is found, the genetic changes that are present in the leukaemia, AML that has occurred due to previous chemotherapy and the presence of another blood condition that may have caused the acute leukaemia. (cancerinfo.co.in)
  • The risk factors associated in the development of acute myeloid leukaemia are listed below. (cancerinfo.co.in)
  • People exposed to high levels of radiation in the past have a risk of developing acute leukaemia. (cancerinfo.co.in)
  • The risk is higher for acute myeloid leukaemia than acute lymphoblastic leukaemia. (cancerinfo.co.in)
  • This risk is more for acute myeloid leukaemia than ALL. (cancerinfo.co.in)
  • People working in petroleum and chemical industry who are exposed to benzene which they inhale is a risk factor for the development of Acute myeloid leukaemia. (cancerinfo.co.in)
  • Disorders of the blood such as polycythemia vera, myelodysplastic syndrome, myelofibrosis and chronic myeloid leukaemia can all predispose to the development of AML. (cancerinfo.co.in)
  • It is important to note that these symptoms can happen due to other reasons and most patients who have these symptoms do not have a leukaemia. (cancerinfo.co.in)
  • Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. (medifocushealth.com)
  • Clavis Pharma will continue to focus on elacytarabine and its CLAVELA Phase III study in patients with acute myeloid leukaemia (AML) who have failed prior therapy. (technologynetworks.com)
  • Meanwhile, we continue to believe in the potential of elacytarabine, our lead product, to become an effective new treatment option for acute myeloid leukaemia. (technologynetworks.com)
  • Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. (svenskaamlgruppen.se)
  • Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor. (svenskaamlgruppen.se)
  • Patients with leukaemia should be considered for inclusion into clinical trials. (eviq.org.au)
  • A systematic overview of chemotherapy effects in acute myeloid leukaemia. (qxmd.com)
  • Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. (qxmd.com)
  • Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. (qxmd.com)
  • For decades, an induction chemotherapy combining daunorubicin with cytarabine, the so-called '3+7', has remained the standard of care for younger adult patients with AML. (nature.com)
  • Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax , work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (clinicaltrials.gov)
  • I. To determine a tolerable combination of venetoclax plus chemotherapy in pediatric patients with relapsed or refractory acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage. (cancer.gov)
  • I. To estimate the overall response rate to the combination of venetoclax and chemotherapy in pediatric patients with relapsed or refractory AML or acute leukemia of ambiguous lineage. (cancer.gov)
  • To assess the quality of life of pediatric patients with relapsed or refractory AML or acute leukemia of ambiguous lineage undergoing treatment with venetoclax and chemotherapy, and to explore relationships between clinical factors and patient-reported quality of life outcomes. (cancer.gov)
  • PRIMARY OBJECTIVES: I. Determine maximum tolerated dose (MTD) of MEK162 (MEK inhibitor MEK162) in patients with RAS-mutated acute myeloid leukemia (AML) when combined with sequential induction chemotherapy (3+4) as measured by development of grade 3-4 dose-limiting toxicities (DLT). (checkorphan.org)
  • Perform preliminary efficacy analysis of combination of MEK162 and induction chemotherapy (3+4) in patients with RAS-mutated AML by measuring complete remission rate, 2-year overall survival, and duration of response. (checkorphan.org)
  • ATLANTA - Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation compared with standard chemotherapy regimens, according to results from the ADMIRAL phase III clinical trial presented at the AACR Annual Meeting 2019 , March 29-April 3. (aacr.org)
  • Patients with relapsed or refractory FLT3-mutated AML have a particularly poor prognosis, with standard chemotherapy regimens yielding low remission rates and any remissions achieved lasting a short duration, he said. (aacr.org)
  • Of the 371 patients enrolled in the clinical trial, 247 were randomly assigned to gilteritinib and 124 to standard chemotherapy. (aacr.org)
  • At the final analysis, patients assigned gilteritinib were found to have a 36 percent reduction in risk of death compared with those assigned standard chemotherapy. (aacr.org)
  • At 12 months, 37.1 percent of the patients treated with gilteritinib were alive compared with 16.7 percent of those assigned standard chemotherapy. (aacr.org)
  • The combined rate of complete remission (which means a patient has no evidence of disease with full recovery of blood counts) and complete remission with partial hematologic recovery (which means a patient has no evidence of disease with partial recovery of blood counts) was 34.0 percent for those assigned gilteritinib and 15.3 percent for those assigned standard chemotherapy. (aacr.org)
  • Intensive postremission chemotherapy in adults with acute myeloid leukemia. (medscape.com)
  • Estey E , Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. (washington.edu)
  • This phase III trial compares standard chemotherapy to therapy with CPX-351 and / or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. (cancer.gov)
  • Giving CPX-351 and / or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone. (cancer.gov)
  • JZP025-101 is an open-label, multicenter, multi-arm, nonrandomized phase 1b master trial to determine the recommended phase 2 dose (RP2D) of CPX-351 when administered in combination with various targeted agents in previously untreated subjects with Acute Myeloid Leukemia (AML) who are fit to receive intensive chemotherapy (ICT). (cancer.gov)
  • Study CPX351-103 is an open-label, multicenter, phase 1b, safety and PK study to determine the MTD of the combination of CPX 351 and venetoclax when administered to subjects with newly diagnosed AML who are unfit for intensive chemotherapy (ICT). (cancer.gov)
  • To analyze cases of therapy-related acute myeloid leukemia and myelodysplastic syndrome diagnosed after chemotherapy for refractory testicular and extragonadal germ cell tumor in our experience. (bioportfolio.com)
  • A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. (centerwatch.com)
  • The purpose of phase 1 part in this study is to determine the maximum tolerated dose (MTD) and/or recommended expansion dose (RED) of ASP2215 concomitant with cytarabine/idarubicin as induction chemotherapy based on the status of the onset of dose-limiting toxicity (DLT) in newly diagnosed Acute Myeloid Leukemia (AML) subjects. (centerwatch.com)
  • Phase 1 part will also evaluate safety and tolerability and characterize the pharmacokinetic (PK) parameters of ASP2215 concomitant with induction and consolidation chemotherapy as well as evaluate the PK parameters of cytarabine concomitant with ASP2215. (centerwatch.com)
  • AbbVie, a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) who are current smokers. (news-medical.net)
  • 1 ⇓ ⇓ - 4 For patients younger than 60 years, a CR is typically obtained in 65% to 80% of patients, but the majority of these patients will relapse if treated with standard consolidation chemotherapy. (bloodjournal.org)
  • This video highlights a phase II trial that tested the addition of nivolumab to combination induction chemotherapy of cytarabine and idarubicin for patients with newly diagnosed acute myeloid leukemia. (cancernetwork.com)
  • Older patients with acute myeloid leukemia had substantial misperceptions regarding the risks of their treatment, whether intensive or palliative chemotherapy, and the likelihood of cure. (cancernetwork.com)
  • 1-3 The refractoried and relapsed AML patients have very poor prognosis, therefore refractoriness and relapse are the major challenges for the chemotherapy of AML. (careacross.com)
  • Several subsequent studies indicated the influence of MDR1 expression levels in the treatment response and survival of leukemia patients, the frequency of resistance to the chemotherapy increased with increasing MDR1 expression.8,9,10 Previous methods for determination of MDR1 expression have included demonstration of P-glycoprotein by flow cytometry and/or immunohistochemistry, and molecular polymerase chain reaction (PCR)-based assays for RNA expression. (careacross.com)
  • One consortium trial is being sponsored by the NCI and will enroll newly diagnosed patients fit for intensive chemotherapy. (pharmiweb.com)
  • The other trial is sponsored by the HOVON group in Europe and will enroll newly diagnosed patients unfit for intensive chemotherapy. (pharmiweb.com)
  • In both populations, patients treated with GMI-1271 together with standard chemotherapy achieved better than expected remission rates and overall survival compared to historical controls, as well as lower than expected induction-related mortality rates. (pharmiweb.com)
  • Patients with favorable-risk disease generally have excellent outcomes and can be treated with standard chemotherapy. (ascopost.com)
  • no significant difference in cancer remission was seen between patients treated with chemotherapy alone and with lestaurtinib and chemotherapy, according to results in a 2011 report. (wikipedia.org)
  • 60 years with favourable risk disease who were treated with GO in combination with induction chemotherapy showed a significant survival benefit, and a trend was also documented for patients with intermediate risk [ 7 ]. (pubmedcentralcanada.ca)
  • Older patients, including those with intermediate risk cytogenetics, also benefit from the addition of GO to remission induction chemotherapy [ 9 , 10 ]. (pubmedcentralcanada.ca)
  • It is not yet known which combination chemotherapy is more effective in treating acute myeloid leukemia. (uchicagomedicine.org)
  • Chemotherapy/Translational Medicine) V. To compare the complete response rate, disease-free survival (DFS), and overall survival (OS) between patients who receive standard 7+3 therapy or IA to patients who receive IA + vorinostat. (uchicagomedicine.org)
  • In conclusion, approximately half of the patients achieved a CP2/PR after intensive chemotherapy, with a clear survival advantage for responders vs non-responders. (diva-portal.org)
  • This study will examine the appropriate dose and side effects of dasatinib, when it is given with the standard of care chemotherapy for children and adolescents with Acute Myeloid Leukemia (AML). (mycancergenome.org)
  • Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. (springer.com)
  • With new trials like " Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury " and " Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma ", the Magnolia State has established itself as a great location for clinical research studies, particularly in cities like Jackson and Tupelo. (clinicaltrialsgps.com)
  • We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added to induction chemotherapy in patients with acute myelogenous leukemia (AML). (elsevier.com)
  • Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. (uni-hamburg.de)
  • It is recommended that idarubicin hydrochloride injection be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. (nih.gov)
  • Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. (harvard.edu)
  • FLAG), with anthracyclines has become standard chemotherapy for refractory acute myeloid leukemia (AML) in European children and adults. (elsevier.com)
  • Enrolled patients received 7â +â 3 induction chemotherapy of continuous infusion of cytarabine (100 mg/m2 per day on days 1-7) and intravenous bolus of idarubicin (12 mg/m2 per day on days 1-3). (bvsalud.org)
  • The probability that adult patients with de novo acute myeloid leukemia (AML) receiving intensive chemotherapy in the absence of allogeneic hematopoietic stem cell transplantation (Allo-HCT) in first complete remission (CR1) will be disease-free at 10 years after diagnosis, a long-term surrogate of cure, is unknown. (ashpublications.org)
  • In the QuANTUM-R trial, patients with relapsed/refractory AML were randomized to receive quizartinib or physician's choice salvage chemotherapy. (onclive.com)
  • Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov). (jax.org)
  • Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. (qxmd.com)
  • Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study. (qxmd.com)
  • Allogeneic stem cell transplantation (SCT) as treatment for patients with acute myeloid leukemia (AML) aims to combine high-dose chemotherapy with immunotherapy by donor T cells mediating a graft-versus-leukemia (GvL) response. (haematologica.org)
  • The curative potential of the donor-derived allo-immune effect is illustrated by the survival advantage of patients with AML after allogeneic SCT as compared to survival after autologous SCT or high-dose chemotherapy. (haematologica.org)
  • New research suggests that the presence of a specific genetic marker, known as WT1 SNP rs16754, may be associated with reduced toxicity from chemotherapy in African-American and Asian children with acute myeloid leukemia (AML). (bio-medicine.org)
  • Although 60 to 70 percent of children with AML achieve long-term remission after treatment with multi-agent chemotherapy, the treatment-related mortality (TRM) associated with this intensive treatment regimen remains a major concern for this patient population. (bio-medicine.org)
  • Factors associated with a prolonged hospital stay during induction chemotherapy in newly diagnosed high risk pediatric acute lymphoblastic leukemia. (amedeo.com)
  • Stem cell transplantation may be used after chemotherapy as a second phase of treatment and may provide an opportunity for a cure. (aamds.org)
  • PURPOSE: This phase II trial is studying the side effects and how well giving epratuzumab together with cytarabine and clofarabine works in treating patients with relapsed or refractory acute lymphoblastic leukemia. (stanford.edu)
  • Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. (amedeo.com)
  • Neurotoxicity more likely in Hispanic children treated for acute lymphoblastic leukemia. (amedeo.com)
  • Growth hormone deficiency and neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia. (amedeo.com)
  • BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat? (amedeo.com)
  • Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. (amedeo.com)
  • Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. (uni-hamburg.de)
  • Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006. (svenskaamlgruppen.se)
  • Researchers studied the cooperation between activated JAK3/STAT5 signaling and HOXA9 overexpression, two events identified as significantly co-occurring in T-cell acute lymphoblastic leukemia. (hematopoiesisnews.com)
  • Researchers investigated the effectiveness of Apatinib, a novel receptor tyrosine kinase inhibitor selectively targeting VEGFR-2 in acute lymphoblastic leukemia (ALL) cells. (hematopoiesisnews.com)
  • Attention is focused on clonal myeloid disorders, acute lymphoblastic leukemia, lymphoma, and plasma cell dyscrasias. (ascopost.com)
  • 97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype. (amedeo.com)
  • Pediatric acute lymphoblastic leukemia-Conquering the CNS across the choroid plexus. (amedeo.com)
  • Pseudo Chediak-Higashi anomaly in blasts from acute lymphoblastic leukemia. (amedeo.com)
  • Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol. (semanticscholar.org)
  • Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. (semanticscholar.org)
  • Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States. (medscape.com)
  • Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. (medscape.com)
  • Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (medscape.com)
  • The updates described in this article focus on the acute promyelocytic leukemia (APL) section, featuring recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and providing guidance on maintenance strategies for APL. (jnccn.org)
  • Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. (uni-hamburg.de)
  • Treatment for acute myeloid leukemia (AML) - or the subtype acute promyelocytic leukemia - is highly complex, so it's important to be treated at a specialized center with expertise in AML. (seattlecca.org)
  • Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. (svenskaamlgruppen.se)
  • Patients with APL (acute promyelocytic leukemia) with PML-RARA are not eligible. (kofam.ch)
  • 2 However, increasing the daily dose of daunorubicin from 45 to 90 mg/m 2 has been associated with higher complete remission (CR) and overall survival (OS) rates, demonstrating that anthracycline intensification could be a critical issue during the induction phase. (nature.com)
  • Bone marrow aspiration was performed at day 15 (d15), and if residual leukaemic blasts were observed (cutoff, 5%) a second course was given with 35 mg/m 2 daunorubicin or 8 mg/m 2 idarubicin, both on days 17 and 18 (to deliver 40% of the total initial dose), and 1000 mg/m 2 cytarabine every 12 h on days 17-20. (nature.com)
  • High-dose daunorubicin in older patients with acute myeloid leukemia. (medscape.com)
  • Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. (medscape.com)
  • Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. (medscape.com)
  • The FDA has approved a fixed combination of daunorubicin and cytarabine (Vyxeos) for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) as well as AML with myelodysplasia-related changes. (cancernetwork.com)
  • Whether Idarubicin can overcomes multidrug resistant 1 induced chemoresistance with higher induction remission rate than daunorubicin in de novo acute myeloid leukemia patients.Whether induction therapy with IA regimen has a higher remission quality with AML patients than that of DA regimen in high MDR1 expression AML patients. (careacross.com)
  • This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia. (uchicagomedicine.org)
  • I. To compare event-free survival (EFS) between patients with acute myeloid leukemia (AML) who receive standard 7+3 (cytarabine and daunorubicin hydrochloride) or idarubicin and high-dose cytarabine (IA) to patients who receive IA + vorinostat. (uchicagomedicine.org)
  • ARM I: Patients receive standard dose cytarabine intravenously (IV) continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. (uchicagomedicine.org)
  • Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group. (medscape.com)
  • Idarubicin hydrochloride is a DNA-intercalating analog of daunorubicin which has an inhibitory effect on nucleic acid synthesis and interacts with the enzyme topoisomerase II. (nih.gov)
  • A prospective single arm phase II study (CTRI/2017/02/007757) was carried out at our center to evaluate the safety and efficacy of outpatient cytarabine, daunorubicin, and etoposide (ADE) regimen in pediatric AML (≤18 years) at the first relapse. (qxmd.com)
  • The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. (qxmd.com)
  • Ziel dieser Studie ist es festzustellen, ob die kombinierte Behandlung mit Midostaurin und der Standard-Chemotherapie (einschliesslich Daunorubicin oder Idarubicin und Cytarabin) bei der Behandlung von AML ohne FLT3-Mutation sicher ist und zu vergleichen, ob sie auch wirksamer ist als die Behandlung mit Placebo und Standard-Chemotherapie. (kofam.ch)
  • Patienten werden nach dem Zufallsprinzip einer Behandlung mit Midostaurin oder Placebo zugewiesen, jeweils in Kombination mit der Standard-Chemotherapie, Daunorubicin oder Idarubicin und Cytarabin. (kofam.ch)
  • This phase III trial comparing idarubicin with high-dose daunorubicin as part of induction therapy in AML did not find significant differences in complete remission rates, relapse, or survival. (ascopost.com)
  • A significant interaction between the treatment arm and the FLT3-ITD mutation was found, and high-dose daunorubicin was more effective than idarubicin in patients with FLT3-ITD mutation. (ascopost.com)
  • Some of the drugs most commonly used include cytarabine (also called cytosine arabinoside or ara-C.) and an anthracycline (such as daunorubicin or idarubicin). (aamds.org)
  • HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. (nih.gov)
  • 2017. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. (uib.no)
  • Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. (medscape.com)
  • Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. (medscape.com)
  • Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. (amedeo.com)
  • The most significant effort was invested in developing lestaurtinib for the treatment of acute myelogenous leukemia (AML). (wikipedia.org)
  • Early studies have suggested that increasing doses of anthracycline improve outcome in younger patients with acute myelogenous leukemia (AML), but dose escalation has been precluded by the acute and chronic toxicities of these agents. (elsevier.com)
  • This Phase I study is for children and adolescents who have acute myelogenous leukemia ( AML ) that has come back (relapsed) or has become resistant (refractory) to standard therapies. (mycancergenome.org)
  • Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. (springer.com)
  • Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. (springer.com)
  • Epidemiology of childhood acute myelogenous leukemia. (medscape.com)
  • Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. (uni-hamburg.de)
  • Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. (uni-hamburg.de)
  • Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. (uni-hamburg.de)
  • Acute myeloid (myelogenous, myelocytic, myeloblastic) leukemia (AML) consists of a group of malignant disorders characterized by the replacement of normal bone marrow with abnormal, primitive hematopoietic cells. (medscape.com)
  • 2008. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. . (fredhutch.org)
  • I. To determine the complete response rate (CR) of cladribine in combination with idarubicin and cytarabine (araC) in patients with acute myeloid leukemia (AML), high risk (HR) myelodysplastic syndrome (MDS), or myeloid blast phase of chronic myeloid leukemia (CML). (clinicaltrials.gov)
  • I. To determine the overall response rate (ORR) of cladribine in combination with idarubicin and araC in patients with AML, HR MDS, or myeloid blast phase of CML. (clinicaltrials.gov)
  • This is a phase 1/2, dose-escalation trial of Lenalidomide given in combination with idarubicin + cytarabine. (clinicaltrials.gov)
  • Identify the safety and recommended phase 2 dose of ibrutinib in combination with idarubicin/cytarabine in relapsed/refractory acute myeloid leukemia (AML). (clinicaltrials.gov)
  • Assess the induction response rate (complete remission [CR]/complete remission with incomplete count [CRi]) of ibrutinib in combination with idarubicin/cytarabine in relapsed/refractory AML. (clinicaltrials.gov)
  • Assess overall survival of ibrutinib in combination with idarubicin/cytarabine in relapsed/refractory AML. (clinicaltrials.gov)
  • This single-arm, phase 2 part of the phase 1-2 study of nivolumab in combination with idarubicin and cytarabine was done at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). (fluidigm.com)
  • A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. (medscape.com)
  • We previously showed SDF-1 (CXCL-12), a chemokine readily abundant within the bone marrow microenvironment, induces apoptosis in acute myeloid leukemia (AML) cells that express high levels of the SDF-1 receptor CXCR4. (jimmunol.org)
  • In recent years, the protective regions of the bone marrow microenvironment, including the endosteal niche, have come to the forefront as targets to enhance the elimination of acute myeloid leukemia (AML) cells. (jimmunol.org)
  • Although many patients typically achieve remission with standard chemotherapeutic treatments, the subsequent relapse experienced by most patients is likely because of those AML cells that survive the treatments within the endosteal niche: the area where the ossified bone and bone marrow interact ( 1 - 5 ). (jimmunol.org)
  • Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. (bioportfolio.com)
  • A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL). (bioportfolio.com)
  • Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting? (amedeo.com)
  • Studies of cellular (nucleated blood and bone marrow cells) drug concentrations in leukemia patients have shown that peak cellular idarubicin concentrations are reached a few minutes after injection. (nih.gov)
  • Methods: Patients with AML aged between 2 and 20 years old, who had the first bone marrow (BM) relapse or induction failure, were enrolled. (elsevier.com)
  • The cells are phenotypically similar to bone marrow-hematopoietic stem cells, and are able to differentiate into both myeloid and lymphoid lineages in vitro . (hematopoiesisnews.com)
  • Researchers conducted a phase III, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors to compare two-year survival probabilities with the use of an intention-to-treat analysis. (hematopoiesisnews.com)
  • Researchers showed that high constitutive expression of migration inhibitory factor (MIF) in acute myeloid leukemia (AML) blasts in the bone marrow is hypoxia-driven and, through knockdown of MIF, HIF1α and HIF2α, establish that hypoxia supports AML tumor proliferation through HIF1α signaling. (hematopoiesisnews.com)
  • Patients who achieved complete remission (CR) received 3 courses of high-dose cytarabine. (bloodjournal.org)
  • HLA-mismatched microtransplant offers good complete remission rates in older patients with acute myeloid leukemia, according to a new study. (cancernetwork.com)
  • However, about 20%-40% of the patients with refractory AML fail to achieve complete remission (CR) and approximately 50% of the CR patients will relapse eventually. (careacross.com)
  • 1 Complete remission (CR) was achieved in 35%-40% of adult patients aged 60 years or younger and 5%-15% among patients older than 60 years of age. (bmj.com)
  • Stratum II (Poor risk patients): Patients experiencing complete remission with or without platelet recovery will begin consolidation therapy within 4-8 weeks of response assessment in the absence of unacceptable toxicity. (knowcancer.com)
  • Patients achieving complete remission (CR) or complete remission with incomplete platelet recover (CRi) may proceed to allogeneic hematopoietic stem cell transplant (HSCT) or to consolidation therapy. (uchicagomedicine.org)
  • Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. (semanticscholar.org)
  • Overall, 19 patients (61%) achieved complete remission (CR) and three had CR with incomplete platelet recovery. (elsevier.com)
  • Although only one patient with late relapse achieved complete remission, minimal residual disease was positive on both flow cytometry and Wilms' tumor 1 mRNA. (elsevier.com)
  • The primary endpoint was a composite including the proportion of patients achieving complete remission and those with a complete remission with incomplete neutrophil or platelet count recovery. (bvsalud.org)
  • Composite remission was 64% (two-stage 95% CI 48-79), with 20 (51%) of 39 patients achieving complete remission and five (13%) achieving complete remission with incomplete neutrophil or platelet count recovery. (bvsalud.org)
  • Approximately 40% children with acute myeloid leukemia (AML) invariably relapse, after attaining the first complete remission (CR), with dismal long-term outcome. (qxmd.com)
  • Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. (nih.gov)
  • A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. (nih.gov)
  • The purpose of this study is to determine the activity of SY-1425 in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are posi. (bioportfolio.com)
  • The novel agent ivosidenib is well tolerated and induces durable responses in patients with relapsed/refractory acute myeloid leukemia and other hematologic malignancies. (cancernetwork.com)
  • GlycoMimetics, Inc. (NASDAQ: GLYC) announced today its design for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate GMI-1271 in combination with MEC (Mitoxantrone, etoposide and Ara-C) or in combination with FAI (fludarabine, cytosine arabinoside and idarubicin) in individuals with relapsed/refractory acute myeloid leukemia (AML). (pharmiweb.com)
  • A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia. (cancerindex.org)
  • PURPOSE Patients with relapsed or refractory acute myeloid leukemia have a poor prognosis. (semanticscholar.org)
  • Jorge E. Cortes, MD, deputy chair of the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the data from the QuANTUM-R trial presented at the 2018 ASH Annual Meeting in relapsed/refractory acute myeloid leukemia (AML). (onclive.com)
  • 2009. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. . (fredhutch.org)
  • The trial's protocol provides for administration of the investigational drug in combination with MEC (mitoxantrone, etoposide and ara-C) or in combination with FAI (fludarabine, ara-C and idarubicin), both of which are standard of care for this indication in the United States. (pharmiweb.com)
  • Flinn IW, Byrd JC, Morrison C et al (2000) Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. (springermedizin.de)
  • Morrison VA, Rai KR, Peterson BL et al (2002) Therapy-related myeloid leukemias are observed after treatment with fludarabine and chlorambucil: results of an intergroup study, Cancer and Leukemia Group B 9011. (springermedizin.de)
  • Carney DA, Westerman DA, Tam CS et al (2010) Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination therapy. (springermedizin.de)
  • This study evaluated the efficacy and safety of combining idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) in adults with newly diagnosed acute myeloid leukemia (AML). (ahdbonline.com)
  • Patients were administered a lymphodepleting regimen (fludarabine 25-30 mg/m 2 daily for 3 Days and cyclophosphamide 300 mg/m 2 daily for 3 Days) followed by a single dose of CD123 CAR T cells at two different dose levels (DL) including 50M (DL1, n = 2) or 200M (DL2, n = 4). (amlglobalportal.com)
  • Researchers performed a phase II trial to evaluate the efficacy and safety of the modified fludarabine, cytarabine, and attenuated-dose idarubicin regimen in elderly acute myeloid leukemia patients. (hematopoiesisnews.com)
  • A combination of the FLT3 kinase inhibitor quizartinib with 5-azacitidine or low-dose cytarabine is active in patients with FLT3-ITD mutated myeloid leukemias, according to a new study. (cancernetwork.com)
  • The altered profile of cytokine responses in cancer cell types compared to the normal counterparts has allowed the identification of changes in the expression of signaling proteins (as in the case of myeloid leukemias) and cytokine receptors (as in the case of lung epithelial cells) as function of malignant transformation. (roswellpark.org)
  • Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. (klinikum-braunschweig.de)
  • Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are associated with multiple human neoplasms including hematologic malignancies, for example: systemic mast cell disorders ( KIT ), non-CML myeloproliferative neoplasms ( PDGFR ) and subsets of acute leukemias ( FLT3 and KIT ). (biomedcentral.com)
  • Ablation of cyclin D3 in mice bearing Notch1-driven T cell acute lymphoblastic leukemias triggered tumor cell apoptosis. (hematopoiesisnews.com)
  • Univariate analyses showed that patients of the idarubicin arm less frequently relapsed and had an improved 7-year outcome, both in terms of disease-free survival (DFS) and OS ( Figure 2a and Supplementary Figures 2A and 2B ). (nature.com)
  • To assess overall survival (OS) and event free survival (EFS) of patients treated with cladribine, idarubicin, and araC (cytarabine). (clinicaltrials.gov)
  • These survival data combined with gilteritinib's relatively low toxicity establish gilteritinib monotherapy as the new standard of care for patients with relapsed or refractory FLT3-mutated AML," continued Perl. (aacr.org)
  • The longest survival in the gilteritinib arm was seen among patients who proceeded to transplant and then resumed gilteritinib thereafter to prevent relapse, but unfortunately long-term survival was very uncommon on either treatment arm," said Perl. (aacr.org)
  • Patients with myelodysplastic syndrome undergoing a reduced -intensity conditioning regimen prior to allogeneic stem-cell transplantation had similar 2-year survival outcomes as patients who underwent myeloablative conditioning. (medworm.com)
  • Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma. (news-medical.net)
  • The addition of gemtuzumab ozogamicin to induction or maintenance therapy failed to improve the complete response rate or overall survival in patients with acute myeloid leukemia. (bloodjournal.org)
  • Next-generation sequencing could be a powerful and independent predictor for relapse and survival among adults with acute myeloid leukemia. (cancernetwork.com)
  • The long-term survival rate of acute myeloid leukemia (AML) has been significantly prolonged due to the improvement of chemotherapeutic protocols and hemopoietic stem cell transplantation. (careacross.com)
  • Therefore, to increase the survival rates of cancer patients, it is critical that we continue to identify molecular targets for therapeutic intervention. (omicsonline.org)
  • If we accomplish this, we hope GMI-1271 will contribute to prolonged overall survival for relapsed/refractory AML patients. (pharmiweb.com)
  • Ten-year overall survival rates have been shown to be 55% to 81% for patients with favorable profiles, 22% to 39% for those with intermediate-risk profiles, and 10% or less for those with unfavorable profiles. (ascopost.com)
  • To estimate disease-free survival (DFS) among patients who receive transplant. (uchicagomedicine.org)
  • To compare event-free survival (EFS) between patients who receive standard 7 + 3 to patients who receive IA. (uchicagomedicine.org)
  • Relative survival ratios were computed as measures of patient survival. (ashpublications.org)
  • One-year survival improved over time in all age groups, whereas 5- and 10-year survival improved in all age groups, except for patients 80+ years. (ashpublications.org)
  • In contrast, there was no improvement in survival in AML patients with a prior diagnosis of a myelodysplastic syndrome during 1993 to 2005 (n = 219). (ashpublications.org)
  • In a small subpopulation of patients, there was even a potential of long-term survival. (ashpublications.org)
  • 9-12 In addition, allogeneic stem cell transplantation (allo-SCT) reduces the risk of relapse and improves survival in selected patient groups. (ashpublications.org)
  • The trial, which was conducted by partner Clovis Oncology, Inc., showed that there was no difference in overall survival between the two arms in either the primary analysis of the hENT1-low patient population, or in the overall intent-to-treat population. (technologynetworks.com)
  • Contrary to the results of numerous published retrospective studies, the study demonstrated that hENT1 status had no impact on survival for patients with metastatic pancreatic cancer treated with gemcitabine. (technologynetworks.com)
  • Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. (svenskaamlgruppen.se)
  • Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. (svenskaamlgruppen.se)
  • Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. (fredhutch.org)
  • We hypothesized that initial disease control by effective cytoreduction, followed by rapid induction of a profound allo-immune response by donor-lymphocyte infusion during the neutropenic phase, is essential for long-term survival. (haematologica.org)
  • The impact of acute graft- versus -host-disease on survival was calculated with a Cox-regression model including onset of acute graft- versus -host-disease as a time-dependent variable. (haematologica.org)
  • Development of grade 1-3, but not grade 4, acute graft- versus -host-disease was associated with superior survival as compared to absence of graft- versus -host-disease (hazard ratio 0.22, P =0.03). (haematologica.org)
  • ATLANTA, December 8, 2012) Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today at the 54th Annual Meeting of the American Society of Hematology (ASH). (bio-medicine.org)
  • To determine if the presence of SNP rs16754 affected survival, remission, relapse risk, and TRM in pediatric AML patients of different ethnicities, a team of investigators analyzed the DNA of 492 children with AML enrolled in the CCG-2961 protocol, a Phase III Children's Cancer Group trial. (bio-medicine.org)
  • Within each racial subgroup, the five-year overall survival rate was higher in the SNP+ patients. (bio-medicine.org)
  • For patients with chronic myelomonocytic leukemia, the overall response rate was higher for azacitidine plus lenalidomide vs azacitidine alone (68% vs 28%, P = .02) but similar for all arms across cytogenetic subgroups, as was remission duration and overall survival. (ascopost.com)
  • Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. (nih.gov)
  • A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. (bioportfolio.com)
  • How can the signs and symptoms of pediatric acute myelocytic leukemia (AML) be categorized? (medscape.com)
  • Signs and symptoms of pediatric acute myelocytic leukemia (AML) can be divided into the following: (1) those caused by a deficiency of normally functioning cells, (2) those due to the proliferation and infiltration of the abnormal leukemic cell population, and (3) constitutional symptoms. (medscape.com)
  • Overexpressed miR-155 is associated with initial presentation and poor outcome in Chinese pediatric acute myeloid leukemia. (cdc.gov)
  • CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. (medscape.com)
  • Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. (springer.com)
  • Recent clinical protocols involved the treatment of acute myeloid leukemia, acute lymphoid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, prolymphocytic leukemia, hypereosinophilic syndrome, systemic mastocytosis and heparin-induced thrombocytopenia. (stanford.edu)
  • 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. (uib.no)
  • 2017. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. (uib.no)
  • A body of evidence shows that NK cells can exhibit potent anti-tumor activity against chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). (medworm.com)
  • The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. (amedeo.com)
  • therefore, for the tyrosine kinase inhibitors in chronic myeloid leukemia, a tabulated summary is given. (springer.com)
  • Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. (uni-hamburg.de)
  • Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. (uni-hamburg.de)
  • Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimen. (uni-hamburg.de)
  • Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. (uni-hamburg.de)
  • Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country. (uni-hamburg.de)
  • Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. (uni-hamburg.de)
  • PDGFR mutations are frequently found in myeloproliferative disorders, such as Philadelphia chromosome-negative chronic myeloid leukemia (CML), where PDGFR alpha or beta fuses with another gene allowing autoactivation of the tyrosine kinase. (biomedcentral.com)
  • 2015. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression. . (fredhutch.org)
  • Nivolumab to control molecular response in chronic myeloid leukemia. (amedeo.com)
  • Management of melanoma in patients with chronic lymphocytic leukemia. (amedeo.com)
  • Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib. (amedeo.com)
  • The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. (amedeo.com)
  • Identification of new phosphorylation sites of CD23 in B-cells of patients with chronic lymphocytic leukemia. (amedeo.com)
  • OUTLINE: This is a multicenter, phase I, dose-escalation study of clofarabine followed by an randomized phase II study. (clinicaltrials.gov)
  • This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. (centerwatch.com)
  • Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. (springer.com)
  • To clarify the efficacy and the safety of FLAG-idarubicin (IDA) for children prospectively, we planned a multicenter phase II study (AML-R11) by the Japanese Pediatric Leukemia/Lymphoma Study Group. (elsevier.com)
  • Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. (qxmd.com)
  • 2017. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. (uib.no)
  • 2017. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). (uib.no)
  • 2017. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. (uib.no)
  • In 2017, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to GlycoMimetics for uproleselan in this patient population. (pharmiweb.com)
  • Additional details regarding the Phase 3 trial will be provided in the company's fourth quarter and fiscal year 2017 financial results teleconference on Tuesday, March 6, 2018, at 8:30 a.m. (pharmiweb.com)
  • Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. (amedeo.com)
  • At the 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, on Monday 11th December 2017, there was an oral abstract session focused on the use of immune-based therapy in Acute Myeloid Leukemia (AML). (amlglobalportal.com)
  • Giving ibrutinib together with idarubicin and cytarabine may kill more cancer cells. (clinicaltrials.gov)
  • Giving CPX-351 and glasdegib together may slow the growth and spread of cancer in patients with therapy-related acute myeloid leukemia. (cancer.gov)
  • In this interview we discuss a study that examined the risk of acute myeloid leukemia in thyroid cancer patients who have been treated with surgery and radioiodine therapy vs those treated with surgery alone. (cancernetwork.com)
  • Hugo F. Fernandez, MD , Associate Chief of Blood and Marrow Transplantation at Moffitt Cancer Center in Tampa, Florida, spoke with The ASCO Post about how he approaches these patients. (ascopost.com)
  • Cancer immunotherapies are arguably one of the most promising treatments for patients with advanced cancers such as melanoma and lung cancer. (umms.org)
  • A Phase II study in 18 patients with pancreatic cancer was initiated for combination treatment with lestaurtinib and gemcitabine, but efficacy of lestaurtinib was not observed. (wikipedia.org)
  • Testing new drugs in untreated small cell lung cancer may prejudice the results of standard treatment: a phase II study of oral idarubicin in extensive disease. (semanticscholar.org)
  • Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. (medscape.com)
  • Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. (medscape.com)
  • This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer. (jnccn.org)
  • Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. (jnccn.org)
  • Your gift will help support our mission to end cancer and make a difference in the lives of our patients. (mdanderson.org)
  • Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. (harvard.edu)
  • METHODS: We did a single-arm, phase 2 trial of patients recruited from the Dana-Farber/Harvard Cancer Center in the USA. (bvsalud.org)
  • To test the efficacy of targeting D-cyclins in cancer treatment, researchers engineered mouse strains that allowed acute and global ablation of individual D-cyclins in a living animal. (hematopoiesisnews.com)
  • Many studies have reported the promising role of retinoids in attaining better outcomes for adult or pediatric patients suffering from several types of cancer, especially acute myeloid leukemia and neuroblastoma. (beds.ac.uk)
  • This is bad news for patients who suffer from metastatic pancreatic cancer, which is a very difficult condition to treat. (technologynetworks.com)
  • While the cancer research community has seen many significant therapeutic advances over the last decade, only recently have investigators identified how patients' individual genetic makeup influences their short- and long-term response to therapy, demonstrating that while the disease may respond positively to therapy, the patient may not. (bio-medicine.org)
  • Data presented today offer important insights into how and why patients respond to blood cancer treatment," said William G. Woods, MD, moderator of the press conference, Pediatric Hematology/Oncology Director, and the Daniel P. Amos Children's Chair of the Aflac Cancer Center and Blood Disorders Service at Children's Healthcare of Atlanta. (bio-medicine.org)
  • OBJECTIVES: I. Determine the feasibility, toxicity, and antileukemic activity of gemtuzumab ozogamicin (CMA-676) with or without mitoxantrone, etoposide, cytarabine, and idarubicin in elderly patients with acute myeloid leukemia. (knowcancer.com)
  • Most patients received a combination of mitoxantrone (12 mg/m2/d) and etoposide (100 mg/m2/d) together with cytosine arabinoside (1 g/m2 b.i.d) for 4 d. (diva-portal.org)
  • and azacitidine given prior (PRIOR), concurrently (CONCURRENT), or after (AFTER) therapy with idarubicin and etoposide. (springernature.com)
  • 9 Initial phase 2 data for this agent showed promise for patients treated in first relapse. (bloodjournal.org)
  • 2 Mortality in patients with AML can result from treatment-related causes, relapse or primary refractoriness. (bmj.com)
  • All patients should be assessed for risk of relapse. (medscape.com)
  • In AML, a LSC reservoir can lead to disease resistance, relapse and often death in patients. (amlglobalportal.com)
  • ADE is an effective induction regimen for pediatric AML patients at the first relapse with reasonable toxicity profile. (qxmd.com)
  • Researchers utilized a third generation of anti-CD19 chimeric antigen receptor (CAR) T cell vector, which contains the Toll/interleukin-1 receptor domain of Toll-like receptor 2, to generate 1928zT2 T cells targeting CD19, and evaluated the efficacy of 1928zT2 T cells in relapse or refractory B cell acute lymphocytic leukemia patients with extramedullary involvement. (hematopoiesisnews.com)
  • Of these 44 patients, seven were not eligible for cytoreductive treatment because of poor performance status (n=3) or severe graft- versus -host-disease (n=4) at the time of relapse. (haematologica.org)
  • This phase I trial studies the side effects and best dose of venetoclax and cytarabine when given with or without idarubicin hydrochloride in treating pediatric patients with acute myeloid leukemia that does not respond to treatment or has returned after a period of improvement. (cancer.gov)
  • PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of clofarabine and to see how well it works when given together with cytarabine and idarubicin in treating patients with intermediate-risk or high-risk acute myeloid leukemia or high-risk myelodysplasia. (clinicaltrials.gov)
  • To determine the optimum dose of clofarabine in combination with cytarabine and idarubicin in patients with previously untreated intermediate- and high-risk acute myeloid leukemia or high-risk myelodysplasia. (clinicaltrials.gov)
  • To determine the safety and tolerance of this regimen in order to determine the recommended phase II dose. (clinicaltrials.gov)
  • Dose escalation of Lenalidomide only will take place, while the doses of idarubicin and cytarabine will be constant. (clinicaltrials.gov)
  • During phase 2, the efficacy of this combination of Lenalidomide + idarubicin + cytarabine, at the maximum tolerated dose (MTD) for Lenalidomide (determined during phase 1), will be tested. (clinicaltrials.gov)
  • Efficacy and safety analyses were done in all patients who received at least one dose of study treatment. (fluidigm.com)
  • The purpose of this study is to determine the safety profile, tolerability and the Recommended Phase 2 Dose of the combination S64315 with venetoclax in patients with Acute Myeloid Leukaem. (bioportfolio.com)
  • Anthracycline dose intensification in acute myeloid leukemia. (medscape.com)
  • Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. (medscape.com)
  • A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. (medscape.com)
  • Thall P, Nguyen H, Estey E . Patient-specific dose finding based on bivariate outcomes and covariates. (washington.edu)
  • This phase Ib trial studies the best dose of gemtuzumab ozogamicin when given together with CPX-351 in treating patients with acute myeloid leukemia that has come back after it was previously in remission. (cancer.gov)
  • This phase I trial studies the side effects and best dose of ipilimumab in treating patients with high-risk myelodysplastic syndrome or acute myeloid leukemia that has come back or no long. (bioportfolio.com)
  • This study is composed of Phase 1 part (the dose-evaluation part and the expansion part) and Phase 2 part. (centerwatch.com)
  • In the dose-evaluation part of Phase 1 part, at least 3 subjects will receive ASP2215 at each dose (low, middle, and high) for determination of MTD and/or RED. (centerwatch.com)
  • In the expansion part of Phase 1 part, a maximum of 3 subjects will receive ASP2215 at RED that has been recommended in the dose-evaluation part and the safety will be assessed based on the onset of DLTs during Cycle 1 of the induction and consolidation periods. (centerwatch.com)
  • In Phase 2 part, Subjects will receive ASP2215 at the recommended dose established in Phase 1 part. (centerwatch.com)
  • Initial Phase I studies with lestaurtinib involved determination of pharmacokinetic parameters following a single dose in healthy volunteers. (wikipedia.org)
  • ARM II: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. (uchicagomedicine.org)
  • We report the results of a phase I study of dose escalation of idarubicin with amifostine and high-dose ara-C in patients with relapsed or refractory AML or myelodysplastic syndrome (MDS). (elsevier.com)
  • Five patients were treated at an idarubicin dose of 18 mg/m 2 /day x 3, three of whom developed grade 3 diarrhea or mucositis. (elsevier.com)
  • Subsequently, three additional patients were treated at a dose of 15 mg/m 2 x 3 days, all of whom experienced grade 3 diarrhea or mucositis. (elsevier.com)
  • The addition of amifostine does not allow dose escalation of idarubicin when combined with high-dose ara-C. (elsevier.com)
  • Cytarabine dose for acute myeloid leukemia. (springer.com)
  • The recommended dose of bortezomib for phase II studies with idarubicin and cytarabine is 1.5 mg/m 2 . (elsevier.com)
  • Lihua Budde reported results from the first-in-human phase I dose-escalation study ( NCT02159495 ) of CD123- Chimeric Antigen Receptor (CAR) T cell therapy in patients with CD123+ Relapsed or Refractory (R/R) AML and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). (amlglobalportal.com)
  • Standard induction therapy for acute myeloid leukemia (AML) is a combination of cytarabine and an anthracycline. (bloodjournal.org)
  • The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin. (semanticscholar.org)
  • Idarubicin hydrochloride injection contains idarubicin hydrochloride, USP and is a sterile, semi-synthetic, preservative-free solution (PFS) antineoplastic anthracycline for intravenous use. (nih.gov)
  • This phase I trial studies the MEK inhibitor MEK162 to see if it is safe in patients when combined with idarubicin and cytarabine. (checkorphan.org)
  • A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk mye. (uni-hamburg.de)
  • Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies. (bioportfolio.com)
  • Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia. (bioportfolio.com)
  • Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. (amedeo.com)
  • In an effort to further improve long-term outcomes, clinical trials testing gilteritinib in combination with other therapies for relapsed or refractory FLT3-mutated AML and testing gilteritinib as frontline therapy for newly diagnosed patients have already been launched. (aacr.org)
  • His clinical research interest focuses on the development of novel therapeutic regimens for patients with acute leukemia, with special interest in the development of novel therapeutic strategies for patients with acute myeloid leukemia. (stanford.edu)
  • He is the leader in several institutional investigator initiated clinical trials, active investigator in collaborative multi-institutional clinical studies and an active member of the SWOG acute leukemia panel. (stanford.edu)
  • My clinical activities combine the development of novel therapeutic modalities, translational research activities and epidemiological study of acute leukemia. (stanford.edu)
  • 22 Furthermore, we have reported that CXCR4 inhibition increased the sensitivity of FLT3/ITD AML cells to apoptosis induced by the FLT3 inhibitor sorafenib in stromal cocultures, 23 and have initiated a clinical trial to validate this concept in patients using sorafenib and the CXCR4 antagonist AMD3100 ( NCT00943943 ). (bloodjournal.org)
  • Guideline] NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia Version 2.2018. (medscape.com)
  • Clinical Trials Referral Resource is designed to serve as a ready reference for oncologists to help identify clinical trials that might be suitable for their patients. (cancernetwork.com)
  • Currently in the United States less than 10% of eligible adult patients are entered into clinical trials. (cancernetwork.com)
  • 1. New designs for clinical trials - patients and physician are poorly served by the current phase 1-phase 2-phase 3 paradigm. (washington.edu)
  • Estey E , Thall PF: New designs for phase II clinical trials. (washington.edu)
  • The clinical spectrum of adult acute myeloid leukemia associated with core binding factor translocations. (washington.edu)
  • In a clinical pilot trial, peri-transplant uric acid depletion reduced acute graft-versus-host disease incidence. (medworm.com)
  • NCI's basic information about clinical trials explains the types and phases of trials and how they are carried out. (cancer.gov)
  • This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in patients with acute myeloid leukemia. (bloodjournal.org)
  • GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in the company's Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory AML. (pharmiweb.com)
  • The company anticipates the initiation of two complementary Phase 2/3 trials from two leading clinical consortia in early 2019. (pharmiweb.com)
  • The dosing of the first patient in our pivotal Phase 3 trial for uproleselan is an important milestone for GlycoMimetics," said Helen Thackray, M.D., FAAP, Senior Vice President, Clinical Development, and Chief Medical Officer of GlycoMimetics. (pharmiweb.com)
  • In a Phase 1/2 clinical trial, uproleselan was evaluated in both newly diagnosed elderly and relapsed/refractory patients with AML. (pharmiweb.com)
  • GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. (pharmiweb.com)
  • Our development strategy now sets us up for multiple, value-creating clinical data readouts, the first of which is topline data from the ongoing Phase 3 trial of rivipansel in sickle cell disease in the second half of 2018," Ms. King added. (pharmiweb.com)
  • GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in a Phase 1 clinical trial for the treatment of multiple myeloma. (pharmiweb.com)
  • the results, reported in 2005, indicated that twice as many patients showed a clinical response when treated with lestaurtinib as compared to those not treated. (wikipedia.org)
  • Additional clinical trials have been initiated since this Phase III trial. (wikipedia.org)
  • Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. (springermedizin.de)
  • These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. (jnccn.org)
  • The first-of-its-kind Phase II clinical trial is based on research into these precancerous growths by Jianjun Zhang, M.D., Ph.D., assistant professor of Thoracic/Head and Neck Medical Oncology. (mdanderson.org)
  • The platform is one of the research engines driving MD Anderson's Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients' lives. (mdanderson.org)
  • Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. (cdc.gov)
  • Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. (medifocushealth.com)
  • These results will be correlated with outcome after treatment and clinical parameters in a consecutive cohort of newly diagnosed patients treated on clinical trials. (grantome.com)
  • The UMCC has a large population of leukemia patients, extensive preliminary data on the proposed projects, a history of productive clinical-laboratory interactions and represents an excellent environment in which to study these important questions. (grantome.com)
  • We remain focused on completing the ongoing clinical trials in which elacytarabine is being investigated and in particular look forward to reporting the results from the pivotal Phase III CLAVELA study in the first quarter of 2013. (technologynetworks.com)
  • Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. (amedeo.com)
  • A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia. (amedeo.com)
  • Gilteritinib was approved by the U.S. Food and Drug Administration (FDA) for treating adult patients who have relapsed or refractory AML that tests positive for a FLT3 mutation in November 2018. (aacr.org)
  • The single pivotal trial is planned to enroll 380 adult patients worldwide and is expected to begin in the third quarter of 2018. (pharmiweb.com)
  • Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia. (bioportfolio.com)
  • The advent of high-throughput gene sequencing has revolutionized our understanding of the genetic mutations that drive myeloid malignancies. (bioportfolio.com)
  • Myeloid malignancies comprise the various myeloid proliferative stem cell disorders. (springer.com)
  • AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO twice daily (BID) on days 6-19 or gilteritinib PO once daily (QD) on days 1-14. (clinicaltrials.gov)
  • thus, a small minority of patients in both arms received prior FLT3-targeted therapy. (aacr.org)
  • Fms-like tyrosine kinase-3 (FLT3) inhibitors have been used to overcome the dismal prognosis of acute myeloid leukemia (AML) with FLT3 mutations. (bloodjournal.org)
  • Activating mutations of the Fms-like tyrosine kinase-3 gene ( FLT3 ) occur in ∼ 30% of patients with acute myeloid leukemia (AML), and are associated with poor prognosis. (bloodjournal.org)
  • 1 - 3 FLT3 mutations consist of 2 major types: internal tandem duplication (ITD) of the juxtamembrane domain region (20%-25% of AML patients) and kinase domain (KD) point mutations mostly in codons 835 and 836 (∼ 7% of AML patients). (bloodjournal.org)
  • Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. (cancer.gov)
  • Phase 2 cohort will also evaluate safety and characterize the PK parameters of ASP2215 in combination with induction and consolidation therapy followed by maintenance therapy in newly diagnosed FLT3-mutated AML subjects. (centerwatch.com)
  • Poor prognosis is associated with the FLT3-ITD mutation, which we see in about one-third of patients. (ascopost.com)
  • 2 They showed that in patients with intermediate-risk AML, the mutant FLT3-ITD was associated with an adverse outcome regardless of other mutations. (ascopost.com)
  • In patients with wild-type FLT3, the presence of several additional mutations -DNMT3A, PHF6, ASXL1, MLL, RAS, WT1 and TP53- conferred a worse prognosis. (ascopost.com)
  • It is very important for FLT3- positive patients to receive better therapy, and while we have no real options now, we believe this will change in the near future. (ascopost.com)
  • A phase II study with sorafenib (Nexavar) was encouraging for patients with FLT3-ITD , and this is the only agent we have available for this purpose. (ascopost.com)
  • At least now, we have proof of principle that FLT3 inhibition can positively impact outcomes in these patients. (ascopost.com)
  • Patients with FLT3 mutations were eligible to receive sorafenib. (ahdbonline.com)
  • Quizartinib was recently demonstrated to be a selective FLT3 inhibitor with excellent pharmacokinetics and promising in vivo activity in a phase II study for FLT3 ITD + AML patients. (biomedcentral.com)
  • Venclexta (venetoclax) in combination with Dacogen (decitabine) is included in guidelines for adult patients with acute myeloid leukemia harboring a FLT3 mutation (NCCN.org). (jax.org)
  • Details of the treatments and results of the consolidation phase including autologous and allogeneic stem cell transplantation (allo-SCT) have been reported elsewhere. (nature.com)
  • Responders received either up to five consolidation cycles of attenuated doses of idarubicin and cytarabine, or allogeneic stem cell transplantation if eligible. (fluidigm.com)
  • 3. Poor risk patients with age below 50 yrs without a HLA matched sibling donor, but with a phenotypically matched unrelated donor may proceed to marrow ablative treatment and allogeneic stem cell transplantation as soon as they have entered CR. (isrctn.com)
  • Poor risk patients in PR after cycle II with a HLA matched family donor (and patient s age below 55 years) or with a phenotypically matched unrelated donor (and patient s age below 50 years) may proceed to allogeneic stem cell transplantation. (isrctn.com)
  • Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. (svenskaamlgruppen.se)
  • The prognosis of patients with relapsed acute myeloid leukemia after allogeneic transplantation is poor. (haematologica.org)
  • In conclusion, efficient cytoreduction followed by donor-lymphocyte infusion and subsequent interferon-α leading to limited acute graft- versus -host-disease represents a potentially curative option for patients with relapsed acute myeloid leukemia after allogeneic transplantation. (haematologica.org)
  • 2 1 The importance of the GvL response is further supported by donor versus no donor comparisons in patients who are potential candidates for allogeneic SCT, favoring the outcome of patients with a stem cell donor. (haematologica.org)
  • Patients are randomized to 1 of 2 treatment arms. (clinicaltrials.gov)
  • Idarubicin and Cytarabine combination therapy is a standard treatment for patients with acute myeloid leukemia (AML). (clinicaltrials.gov)
  • Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms. (clinicaltrials.gov)
  • After completion of study treatment, patients are followed up for 6 months. (clinicaltrials.gov)
  • After completion of study treatment, patients are followed up every 3 months for 2 years and then annually thereafter for 3 years. (knowcancer.com)
  • Giving MEK inhibitor MEK162, cytarabine, and idarubicin may be an effective treatment for acute myeloid leukemia. (checkorphan.org)
  • After completion of study treatment, patients are followed up for 30 days. (checkorphan.org)
  • In addition, the relatively low toxicity of gilteritinib and the fact that it is an oral therapy means physicians can manage patients in the outpatient setting, which is a paradigm shift for the treatment of this disease. (aacr.org)
  • What are the postremission treatment recommendations for better-risk patients with acute myeloid leukemia (AML)? (medscape.com)
  • This phase II trial studies how well CPX-351 and glasdegib work for the treatment of therapy-related acute myeloid leukemia. (cancer.gov)
  • Treatment of AML in Phase 1 part is composed of 3 periods of therapy: remission induction, consolidation, and maintenance. (centerwatch.com)
  • Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. (news-medical.net)
  • A novel risk classification scheme based on expression of 36 micro-RNA samples was able to identify pediatric patients with acute myeloid leukemia at high or low risk of experiencing treatment failure, according to a new analysis. (cancernetwork.com)
  • The FDA has approved gemtuzumab ozogamicin (Mylotarg) for the first-line treatment of adults with CD33-positive AML and for pediatric patients with relapsed or refractory CD33-positive AML. (cancernetwork.com)
  • Method and analysis We will conduct a systematic review of randomised controlled trials that investigate the effect and safety of GO for the treatment of patients with AML. (bmj.com)
  • Getting more patients to transplant following treatment with GMI-1271 is one of our goals for this therapy. (pharmiweb.com)
  • Treatment in this patient population was well tolerated, with minimal adverse effects. (pharmiweb.com)
  • With the emergence of molecular diagnostics and new therapeutics, the treatment of acute myeloid leukemia (AML) is entering a new era. (ascopost.com)
  • A Phase I study of 47 patients reported in 2010 that treatment of refractory neuroblastoma was well tolerated at the recommended doses, and an additional Phase I study in children with refractory neuroblastoma was completed in 2011. (wikipedia.org)
  • Patients with residual blasts may receive re-induction treatment beginning on day 15. (uchicagomedicine.org)
  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. (springer.com)
  • Idarubicin in induction treatment of acute myeloid leukemia in the elderly. (springer.com)
  • Chustecka Z. FDA approves Mylotarg for treatment of acute myeloid leukemia. (medscape.com)
  • Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. (medscape.com)
  • Patients who are not eligible for Allo-SCT or who do not meet the eligibilty criteria for randomisation will receive cycle III as consolidation treatment. (isrctn.com)
  • The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies. (mdanderson.org)
  • Treatment protocols for acute myeloid leukemia (AML) are provided below, including a general treatment approach and treatment recommendations for relapsed or refractory disease. (medscape.com)
  • Two patients were alive in remission following hematopoietic stem cell transplantation, whereas the other five patients died of either the disease or treatment-related causes. (elsevier.com)
  • Additionally, infusions of up to 200M CAR T cells are safe with no treatment related AEs observed and "promising anti-leukemic activity" was observed in patients with R/R AML. (amlglobalportal.com)
  • With the exception of Ph+ALL, no TKIs have been approved for treatment of acute leukemia so far. (biomedcentral.com)
  • The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. (medifocushealth.com)
  • The development of drug resistance in leukemia cells constitutes the major reason for treatment failure in acute myeloid leukemia (AML). (grantome.com)
  • Our physician-scientists have been at the forefront of this research for decades to help bring our patients the best treatment options possible. (seattlecca.org)
  • Acute myeloid leukemia treatment is generally done in two phases. (seattlecca.org)
  • Thirty-two patients received cytoreductive treatment, followed by donor-lymphocyte infusion in 22 patients. (haematologica.org)
  • Current studies take these insights a step further, examining specific patient subpopulations to determine their risk for negative outcomes and whether early preventive interventions or treatment adjustments may help avoid treatment-related toxicity. (bio-medicine.org)
  • The intensive treatment regimen delivered to patients during CCG-2961 allowed researchers to study the effects of ethnicity on patient outcome, while minimizing non-biological influences such as access to care or oral medication compliance. (bio-medicine.org)
  • Most patients with AML need treatment soon after diagnosis because the disease often progresses fast. (aamds.org)
  • Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia over 45 years of age. (amedeo.com)
  • The aim of this study was to investigate whether 8 known predictors relate differently to outcomes in chiropractic practice and in general practice and to which degree these factors may be helpful in selecting patients benefiting more from one setting or the other. (bvsalud.org)
  • METHODS: Patient characteristics were collected at baseline, and outcomes of pain intensity (numeric rating scale 0-10) and activity limitation (Roland-Morris Disability Questionnaire 0-100) after 2, 12, and 52 weeks. (bvsalud.org)
  • Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. (medscape.com)
  • Research shows patient outcomes are better at Magnet hospitals. (seattlecca.org)
  • Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. (svenskaamlgruppen.se)
  • However, researchers recently discovered that the presence of SNP rs16754 in the WT1 gene is correlated with improved outcomes in pediatric patients with AML. (bio-medicine.org)
  • Based on the fact that the frequency of SNP rs16754 varies by race, researchers assessed the effect of this SNP on outcomes in specific ethnic patient groups. (bio-medicine.org)
  • transplantation (SCT) in patients with AML. (bioportfolio.com)
  • Estey E , de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, Giralt S. Prospective feasibility analysis of reduced intensity conditioning (RIC) regimens for hematopoetic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). (washington.edu)
  • Non-low-risk patients are evaluated for stem cell transplantation in first remission. (medscape.com)
  • Patients in the AML cohort had refractory AML following Allogenic-Hematopoietic Stem Cell Transplantation (allo-HSCT) and a median of six prior lines of therapy). (amlglobalportal.com)
  • Giving CPX-351 and gemtuzumab ozogamicin may work better in treating patients with acute myeloid leukemia, compared to giving only one of these therapies alone. (cancer.gov)
  • Frontline therapy: Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15. (knowcancer.com)
  • Stratum II Consolidation therapy: Patients receive gemtuzumab ozogamicin IV over 2 hours on day 1 and then 1-3 months later. (knowcancer.com)
  • Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. (springermedizin.de)
  • To explore the antitumor activity of this regimen in these patients. (clinicaltrials.gov)
  • 5-Azacitidine administered as a 7-day dosing regimen (7-0-0) is approved in high risk IPSS myelodysplastic syndrome (MDS) patients. (bioportfolio.com)
  • All patients were evaluable for safety and efficacy. (fluidigm.com)
  • To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. (stanford.edu)
  • This is an open‑label non‑randomized two‑center phase 2 study evaluating the safety and efficacy of concurrent therapy with ibrutinib and venetoclax in subjects with relapsed or refractory CLL/SLL. (stanford.edu)
  • To compare the efficacy and safety between hypomethylating agent (HMA) alone and the combination of HMA and histone deacetylase inhibitor (HDACi) in myelodysplastic syndrome (MDS) or acute myeloid leu. (bioportfolio.com)
  • The purpose of phase 2 part is to evaluate efficacy of ASP2215 in combination with induction therapy. (centerwatch.com)
  • The findings indicate that CIA and FIA have similar efficacy in younger patients with newly diagnosed AML. (ahdbonline.com)
  • Data from a Phase II study completed in 2009 and interim results from an elacytarabine/idarubicin combination study completed in 2012 highlight the promising efficacy and safety profile of elacytarabine in AML patients seen to date. (technologynetworks.com)
  • From November 2001 to April 2005, a total of 832 AML patients (15-60 years) were enroled in the LAM-2001 study. (nature.com)
  • Of the 832 patients enroled in the study, 14 were excluded ( Figure 1 ). (nature.com)
  • I. To study and describe the relationship between pretreatment patient/disease characteristics (including AML-associated molecular abnormalities) and outcome. (clinicaltrials.gov)
  • To study and describe the relationship between patient/disease characteristics, use of intrathecal prophylaxis, and incidence of leptomeningeal disease. (clinicaltrials.gov)
  • After completion of study therapy, patients are followed periodically for 12 months. (clinicaltrials.gov)
  • We are specifically not soliciting additional members for the cooperative groups, nor are we suggesting how practicing oncologists should be treating patients who are not in a study. (cancernetwork.com)
  • Adaptive randomized study of Idarubicin and Cytarabine versus Troxacitabine and Cytarabine versus Troxacitabine and Idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. (washington.edu)
  • GSK today announced updated results for Tafinlar (dabrafenib) from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma. (news-medical.net)
  • We have performed a pilot study with a small cohort of AML patients to determine the relationship of MDR1 expression and CR rate of AML patients. (careacross.com)
  • Ethics and dissemination There was no patient involved in this study, therefore no ethical consideration is needed. (bmj.com)
  • During 2019, we anticipate topline data from the Phase 3 study of rivipansel being conducted by Pfizer in patients with sickle cell disease. (pharmiweb.com)
  • This benefit to good risk patients was found in a similar study conducted by the Southwest Oncology Group (SWOG) [ 8 ]. (pubmedcentralcanada.ca)
  • PROJECTED ACCRUAL: A total of 45-82 (28-49 for stratum I, and 17-33 for stratum II) patients will be accrued for this study. (knowcancer.com)
  • Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. (uni-hamburg.de)
  • Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. (uni-hamburg.de)
  • In Amsterdam, NL, during the 24th meeting of the European Hematology Association (EHA), the phase II results of the SAIL study were presented by Professor Walter Fielder , University Medical Center Hamburg-Eppendorf , Hamburg, DE. (aml-hub.com)
  • This study is a multi-center, open-label, non-randomized trial investigating the combination of cytarabine (Ara-C), adarubicin and selinexor (KPT-330) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). (aml-hub.com)
  • The main objective of this phase I study was to evaluate the safety and activity of CD123CAR T cells in patients with R/R AML (Cohort 1, n = 6) and BPDCN (Cohort 2). (amlglobalportal.com)
  • Although QTcF prolongation was a concern based on the initial phase I study, the doses that were used in this trial showed very low QTcF rates, which were not associated with serious arrhythmias or other issues, he adds. (onclive.com)
  • The aim of this randomized phase-II study was to evaluate the effect of substituting cytarabine by azacitidine in intensive induction therapy of patients with acute myeloid leukemia (AML). (springernature.com)
  • A randomized population-based phase II study. (svenskaamlgruppen.se)
  • Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry. (svenskaamlgruppen.se)
  • A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia. (amedeo.com)
  • The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. (amedeo.com)
  • Saphir Interventionsstudie zur Optimierung des präventiven Verhaltens erstgradig Verwandter, die mittelbar durch an kolorektalem Karzinom erkrankte Patienten betroffen sind Verbesserung der Darmkrebsvorsorge bei erstgradig Verwandten von Darmkrebspatienten Einschlusskriterien Intervention (Arzt - Patient) INPUT 45 bis 60 min. (present5.com)
  • Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. (bioportfolio.com)
  • Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. (bioportfolio.com)
  • Arm I: Patients receive idarubicin IV over 5 minutes on days 1, 3, and 5, cytarabine IV continuously on days 1-10, and clofarabine IV over 1 hour on days 2, 4, 6, 8, and 10. (clinicaltrials.gov)
  • Arm II: Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and 10. (clinicaltrials.gov)
  • My special focus is on the development of better, patient tailored therapies for young and elderly patients with acute leukemia. (stanford.edu)
  • MD Anderson's adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches to our patients quickly, safely and effectively. (mdanderson.org)
  • Consolidation therapy: Patients receive cytarabine IV over 2 hours every 12 hours on days 1-6 and idarubicin IV over 5 minutes once daily on days 4-6. (clinicaltrials.gov)
  • OUTLINE: INDUCTION THERAPY: Patients receive MEK inhibitor MEK162 orally (PO) twice daily (BID) on days -4 to -1 and days 5-18, cytarabine intravenously (IV) continuously over 24 hours on days 1-4, and idarubicin IV over 1 hour on days 1-3. (checkorphan.org)
  • POST-REMISSION THERAPY: Patients receive cytarabine IV continuously over 24 hours on days 1-3, idarubicin IV over 1 hour on days 1 and 2, and MEK inhibitor MEK 162 PO BID on days 4-17. (checkorphan.org)
  • For example, is it reasonable to discharge a patient with a low neutrophil count, is a day 14 marrow really necessary, how well do I know this patients' prognosis with standard therapy? (washington.edu)
  • Long-term survivors of Ewing sarcoma (ES) and osteosarcoma may be at risk for therapy-related acute leukemia or myelodysplastic syndrome (t-AL/MDS). (bioportfolio.com)
  • A randomized phase III trial adding the investigational tyrosine kinase inhibitor midostaurin to conventional therapy has been completed and is awaiting maturation. (ascopost.com)
  • Stratum I (Standard risk patients): Patients with disease progression at any time during frontline therapy may begin induction therapy immediately. (knowcancer.com)
  • Patients experiencing partial response are given a second induction therapy course. (knowcancer.com)
  • Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. (springer.com)
  • There were 22 patients of ≥60 years with previously untreated AML (eight with prior myelodysplasia/myeloproliferative disorder or cytotoxic therapy). (elsevier.com)
  • 60-65 years, select patients up to age 75 y) receive intensive therapy. (medscape.com)
  • Less-fit patients (70-75 years and older, or younger patients with significant comorbidities) receive low-intensity therapy. (medscape.com)
  • All seven patients completed the therapy and no early death was observed. (elsevier.com)
  • The speaker noted that the findings of this first-in-human phase I trial of CD123 CAR T cell therapy have demonstrated the safety and feasibility of targeting CD123 in AML. (amlglobalportal.com)
  • The goals of induction therapy are to put your leukemia in remission and ensure you are healthy enough to go on to the next phase, consolidation therapy. (seattlecca.org)
  • However, even this promising differentiation therapy has some limitations: retinoid toxicity and intrinsic or acquired resistance have been observed in many patients. (beds.ac.uk)
  • Prognostic factors can be subdivided into two categories: patient-associated factors and disease-related factors. (bmj.com)
  • An important mutational analysis of 18 genes, performed by Patel et al on the Eastern Cooperative Oncology Group (ECOG) E1900 patient population, found that more extensive mutational analysis can better discriminate patients with AML into various prognostic groups. (ascopost.com)
  • Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. (klinikum-braunschweig.de)
  • Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. (svenskaamlgruppen.se)
  • Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia. (svenskaamlgruppen.se)

No images available that match "patients with acute myeloid phase idarubicin"